Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines.
Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P; EORTC-GELA Lymphoma Group. Girinsky T, et al. Among authors: poortmans p. Radiother Oncol. 2008 Aug;88(2):202-10. doi: 10.1016/j.radonc.2008.05.012. Epub 2008 Jun 12. Radiother Oncol. 2008. PMID: 18555548
Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).
Aleman BM, Girinsky T, van der Maazen RW, Strijk S, Meijnders P, Bortolus R, Olofsen-van Acht MJ, Lybeert ML, Lievens Y, Eghbali H, Noordijk EM, Tomsic R, Meerwaldt JH, Poortmans PM, Smit WG, Pinna A, Henry-Amar M, Raemaekers JM; European Organization for Research; Treatment of Cancer (EORTC) Lymphoma Group. Aleman BM, et al. Among authors: poortmans pm. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1184-90. doi: 10.1016/j.ijrobp.2005.03.044. Epub 2005 Jun 2. Int J Radiat Oncol Biol Phys. 2005. PMID: 15936157
The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study.
Nguyen TD, Poortmans PM, van der Hulst M, Studer G, Pigois E, Collen TD, Belkacemi Y, Beckendorf V, Miralbell R, Scandolaro L, Soete G, Villa S, Gez E, Thomas O, Krengli M, Jovenin N. Nguyen TD, et al. Among authors: poortmans pm. Radiother Oncol. 2005 Dec;77(3):286-9. doi: 10.1016/j.radonc.2005.10.015. Epub 2005 Nov 22. Radiother Oncol. 2005. PMID: 16307812
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Antonini N, et al. Among authors: poortmans p. Radiother Oncol. 2007 Mar;82(3):265-71. doi: 10.1016/j.radonc.2006.09.014. Epub 2006 Nov 28. Radiother Oncol. 2007. PMID: 17126434 Clinical Trial.
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Fermé C, et al. Among authors: poortmans p. N Engl J Med. 2007 Nov 8;357(19):1916-27. doi: 10.1056/NEJMoa064601. N Engl J Med. 2007. PMID: 17989384 Free article. Clinical Trial.
EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.
Matzinger O, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, Poortmans P, Collette L, Kuten A. Matzinger O, et al. Among authors: poortmans p. Radiother Oncol. 2009 Aug;92(2):164-75. doi: 10.1016/j.radonc.2009.03.018. Epub 2009 Apr 15. Radiother Oncol. 2009. PMID: 19375186 Review.
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M; EORTC-GELA H8 Trial Group. Heutte N, et al. Among authors: poortmans p. Lancet Oncol. 2009 Dec;10(12):1160-70. doi: 10.1016/S1470-2045(09)70258-X. Epub 2009 Oct 12. Lancet Oncol. 2009. PMID: 19828373 Clinical Trial.
Reducing interobserver variation of boost-CTV delineation in breast conserving radiation therapy using a pre-operative CT and delineation guidelines.
Boersma LJ, Janssen T, Elkhuizen PH, Poortmans P, van der Sangen M, Scholten AN, Hanbeukers B, Duppen JC, Hurkmans C, van Vliet C. Boersma LJ, et al. Among authors: poortmans p. Radiother Oncol. 2012 May;103(2):178-82. doi: 10.1016/j.radonc.2011.12.021. Epub 2012 Jan 20. Radiother Oncol. 2012. PMID: 22265730
Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial.
Immink JM, Putter H, Bartelink H, Cardoso JS, Cardoso MJ, van der Hulst-Vijgen MHV, Noordijk EM, Poortmans PM, Rodenhuis CC, Struikmans H. Immink JM, et al. Among authors: poortmans pm. Ann Oncol. 2012 Oct;23(10):2591-2598. doi: 10.1093/annonc/mds066. Epub 2012 Apr 12. Ann Oncol. 2012. PMID: 22499858 Free article. Clinical Trial.
431 results